> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 Lots of Quinacrine Dihydrochloride API Recalled
- URL: https://www.fdaweb.com/2-lots-of-quinacrine-dihydrochloride-api-recalled/
- Published: 2019-09-20T12:00:00.000Z
- Updated: 2026-09-15T01:51:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145051

Darmerica has recalled two lots of quinacrine dihydrochloride bulk active pharmaceutical ingredient (API) due to a label mix-up. Quinacrine is used as an antiprotozoal, antirheumatic, intrapleural sclerosing agent. The lots were tested and identified as artemisinin API, which is used for treating malaria. “Receiving artemisinin rather than quinacrine could lead to deterioration of disease that is being treated, serious adverse reactions, due to prolonged exposure to artemisinin, which would need medical or surgical intervention as well as mistaken evaluation and remediation of adverse reactions,” a [recall notice ](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/darmerica-llc-issues-voluntary-nationwide-recall-quinacrine-dihydrochloride-due-labeling-error?ref=fdaweb.com)says.